Pharmacy Drug Policy

SUBJECT: Pulmonary Hypertension (PH)
POLICY NUMBER: PHARMACY-42
EFFECTIVE DATE: 06/2005
LAST REVIEW DATE: 09/14/2026

If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:

Policy Application

Category:	☒ Commercial Group (e.g., EPO, HMO, POS, PPO)	☒ Medicare Advantage
	☒ On Exchange Qualified Health Plans (QHP)	☐ Medicare Part D
	☒ Off Exchange Direct Pay	☒ Essential Plan (EP)
	☒ Medicaid & Health and Recovery Plans (MMC/HARP)	☒ Child Health Plus (CHP)
	☐ Federal Employee Program (FEP)	☐ Ancillary Services
	☒ Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

Pulmonary Hypertension is a type of high blood pressure that occurs when the pressure in the blood vessels that carry blood from the heart to the lungs is higher than normal. Patients with pulmonary hypertension are classified into five groups based upon etiology: Group 1 – pulmonary arterial hypertension (PAH); Group 2 – pulmonary hypertension due to left-sided heart disease; Group 3 – due to chronic lung disorders and hypoxia; Group 4 – Chronic thromboembolic pulmonary hypertension (CTEPH) and other pulmonary artery obstructions; Group 5 – pulmonary hypertension due to unclear or multifactorial mechanisms.

Careful invasive assessment of pulmonary hemodynamics is critical in the evaluation of any patient with suspected pulmonary hypertension (PH). All patients that are suspected of having PH after non-invasive evaluation (chest X-ray and echocardiogram) must undergo right heart catheterization (RHC) to confirm the diagnosis, assess severity of disease and guide medication therapy. RHC values distinguish PAH [World Health Organization (WHO) Group 1], PH-ILD (WHO group 3) and CTEPH (WHO Group 4) and from other types of Pulmonary Hypertension (WHO Groups 2, 5) as the pharmacological treatment of these groups is vastly different. RHC can be performed safely even in most pediatric patients and patients with severe pulmonary hypertension.

Interpretation of Right Heart Catheterization hemodynamic values:

Pulmonary Artery Pressure: mPAP

- Normal mean pulmonary artery pressure is typically 11-17mmHg with an upper limit of normal of approximately 20mmHg. When the mPAP is > 20 mmHg this confirms pulmonary hypertension (further testing is necessary to further classify the specific type of pulmonary hypertension / WHO Group **AND** to determine the appropriate medication treatments)

Pulmonary Capillary Wedge Pressure (PCWP)

- Also referred to as pulmonary artery occlusion pressure (PAOP) or pulmonary artery wedge pressure (PAWP) and estimates (is an indirect measurement of) the left atrial pressure.
- Normal pulmonary capillary wedge pressure (PCWP) varies from 6 to 15 mmHg with a mean of 9 mmHg and measures the left atrial pressure.
- In the diagnosis of WHO Group 1 PAH the PCWP remains within normal range ≤ 15 mmHg.
- An elevated PCWP > 15 mm Hg is not consistent with a diagnosis of WHO Group 1 PAH.

- Conditions that raise left ventricular end-diastolic pressure result in an elevated wedge pressure (> 15 mm Hg) including left ventricular systolic heart failure, left ventricular diastolic heart failure, mitral and aortic valve disease, hypertrophic cardiomyopathy; hypervolemia, right-to-left shunts, cardiac tamponade, and constrictive and restrictive cardiomyopathies.

Pulmonary Vascular Resistance (PVR)

- A measure of the pulmonary blood vessel resistance to blood flow
- Calculated from RHC hemodynamic values including mPAP, pulmonary capillary wedge pressure and cardiac output.
- PVR (wood units) = $\frac{\text{mPAP} - \text{PCWP (mmHg)}}{\text{CO (L/min)}}$
- Pulmonary vascular resistance may be reported in dynes/sec/cm^5. To convert this measurement to wood units, divide by 80.
- For reference a calculator is found at www.easycalculation.com/medical/pulmonary.php Divide result by 80, for wood units.

Group 1 - Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension characterized by sustained elevation of pulmonary artery pressure. The condition is uncommon but is associated with a high mortality rate. Some causes of and risk factors for pulmonary arterial hypertension include congenital heart defects, connective tissue disease (scleroderma), HIV infection, blood clots, liver disease (portal hypertension) and medication (ex. Fen-phen). The disease can also have an unknown cause: idiopathic pulmonary arterial hypertension (PAH). The most common symptoms caused by PAH are unusual fatigue, shortness of breath, chest pain, fainting, and peripheral edema.

Group 2 - Pulmonary hypertension due to left heart disease (PH-LHD) is the most common cause of pulmonary hypertension. Patients with PH-LHD typically present with symptoms and signs related to HF such as dyspnea, fatigue, and signs of pulmonary and/or peripheral edema. Characterized by pulmonary hypertension associated with an elevated left atrial pressure (e.g., mean LA pressure >14 mmHg) resulting in pulmonary venous hypertension (i.e., post-capillary PH). Defined hemodynamically as a mean pulmonary arterial pressure (mPAP) > 20 mmHg and a PCWP > 15 mmHg and normal or reduced cardiac output. Targeted PAH medications (contained within this policy) are not indicated for routine use in PH-LHD. The proceedings of the 7^h World Symposium on Pulmonary Hypertension reinforced prior recommendations against use of PH-targeted therapies in this clinical setting . Further study is required to determine the safety and efficacy of these agents in patients with PH-LHD.

Group 3 - Patients with pulmonary hypertension (PH) due to diffuse lung disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease, or overlap syndromes) or conditions that cause hypoxemia (e.g., obstructive sleep apnea, alveolar hypoventilation disorders) are classified as having group 3 PH. Interstitial Lung disease includes several conditions characterized by scarring (fibrosis) within the lungs such as Idiopathic pulmonary fibrosis (IPF), connective tissue diseases (CTDs), combined pulmonary fibrosis and emphysema (CPFE) and Lymphangioleiomyomatosis (LAM). Pulmonary hypertension frequently complicates the course of patients with ILD (PH-ILD) and is associated with worse functional status measured by exercise capacity, greater supplemental oxygen needs, decreased quality of life, and worse outcomes.

Group 4 - Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of pulmonary hypertension which can lead to right heart failure and death. Common symptoms include dyspnea on exertion, rapid exhaustion, and fatigue. Lung ventilation/perfusion (V/Q scan) is the preferred and recommended screening test. Surgery is the only definitive therapy for CTEPH, with pulmonary thromboendarterectomy (PTE) being the surgical procedure of choice.

Group 5 - Pulmonary hypertension due to unidentified / multifactorial mechanisms includes patients with PH who do not clearly fit into group 1 through 4 pulmonary hypertensions. Contributing diagnoses for PH in this group include those with hematologic disorders such as chronic hemolytic anemia, myeloproliferative disorders, systemic or metabolic disorders including sarcoidosis, pulmonary Langerhans histiocytosis X, neurofibromatosis, Gaucher disease, glycogen storage disease, complex congenital heart disorders except patients with PH due to corrected or uncorrected left to right intracardiac or extracardiac shunts and others including chronic kidney disease or fibrosing mediastinitis.

Treatment goals include improvement in both short-term functional symptoms as well as long-term outcomes such as: dyspnea and exercise endurance, lowering pulmonary artery pressure, reducing hospitalizations, prevent progression of disease, and improve survival.

Medical management addressed in this policy includes the following advanced therapies: endothelial-receptor antagonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), prostacyclin pathway agents (PPAs - treprostinil, epoprostenol, selexipag), soluble guanylate cyclase stimulators (sGCS - riociguat) and the newest agent, an activin signaling inhibitor (ASI - sotatercept-csrk).

(See appendix for Pulmonary Hypertension WHO and Clinical Classification, Hemodynamic classifications of pre- and post-capillary pulmonary hypertension, NYHA Functional Classification, WHO Pulmonary Hypertension Functional Classification, and Pulmonary Hypertension Risk Stratification Tools).

DRUG SPECIFIC POLICIES / CRITERIA:

Adcirca, generic tadalafil (including Alyq*), Tadliq – Pharmacy benefit
Tadalafil is a phosphodiesterase-5 enzyme inhibitor (PDE5) indicated for treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1) to improve exercise ability. *Of Note: Alyq is an FDA-approved generic equivalent to Adcirca; therefore, requests for Alyq will follow the requirements for tadalafil throughout this policy. Where tadalafil is mentioned the use of Alyq will be accepted to satisfy that requirement. 1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND** 2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND** 3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting: • Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND** • Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND** • Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND** 4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND** 5. Adcirca and equivalent generic tadalafil will not be authorized for a diagnosis of erectile dysfunction as there are FDA approved medications for this diagnosis, **AND** 6. Requests for brand name Adcirca will require documentation of serious side effects or drug failure with the equivalent generic tadalafil product indicated for a diagnosis of PAH Dosing guidelines: a. Adcirca, Alyq and generic tadalafil tablet: 40mg orally once daily. b. Tadliq: 40mg (10mL) once daily. Quantity limit: 300 milliliters per 30-day supply.

Adempas (riociguat) – Pharmacy benefit

Adempas (riociguat): is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with:

- Pulmonary arterial hypertension (PAH) (WHO group 1) to improve exercise capacity, improve WHO functional class, and delay clinical worsening.
- Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (World Health Organization [WHO] group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.

Drug Criteria for Pulmonary Arterial Hypertension (PAH):

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must be at least 18 years of age, **AND**
3. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
4. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
5. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
6. Step therapy applies – must have an adequate trial of at least one of the following oral generic *preferred* products with evidence of severe intolerance or drug failure / disease progression despite these treatments:
   a. PDE5 inhibitor: sildenafil or tadalafil
   b. ERA: ambrisentan or bosentan

Drug Criteria for chronic thromboembolic pulmonary hypertension (CTEPH):

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of CTEPH; **AND**
2. Must be at least 18 years of age, **AND**
3. Must have a diagnosis of World Health Organization (WHO) Group 4 CTEPH; **AND**
4. The diagnosis must be confirmed by Right Heart Catheterization (RHC) **AND** ventilation/perfusion scintigraphy (V/Q scan) or pulmonary angiogram (or both); **AND**
5. Right Heart Catheterization must confirm the diagnosis of pulmonary hypertension:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ to 15 mm Hg at rest; **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU); **AND**
6. The patient must have recurrent or persistent disease after surgical intervention **OR**
7. Inoperable disease determined by V/Q scan and/or pulmonary angiography in consultation with an experienced pulmonary thromboendarterectomy center.
8. Progress notes including relevant diagnostic test results (including Right Heart Catheterization **AND** V/Q scan or pulmonary angiography) are required.
9. Requests for the use of Adempas as a bridge to surgery/surgical evaluation require submission of provider rationale for this use, a medical / surgical treatment plan and will be considered on a case-by-case basis. Adempas will *not* be approved as a replacement for surgery in patients who are deemed operable, since surgical intervention is the only curative treatment for CTEPH at this time.
   a. Any approvals for use as a bridge-to-surgery/surgical evaluation will be short-term and limited to the timeframe needed for the surgical evaluation/surgical intervention and post-surgical evaluation to occur per the treatment plan.

b. Requests for recertification / continued coverage as a bridge-to-surgery/surgical evaluation will be reviewed with policy criteria found in 9 above.
c. After surgery/surgical evaluation has occurred, requests for continued coverage of Adempas will be evaluated based on criteria 1-8 above.

Dosing guidelines:
a. Maximum dose of Adempas (riociguat) is 2.5mg three times a day,
b. Of note: active smokers may require a titration above this based on increased drug metabolism. Dosage decrease may be required in patients who stop smoking

Flolan, Veletri, and generic epoprostenol – Medical benefit

Epoprostenol is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (World Health Organization group 1) to improve exercise capacity.

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
5. Commercial, Exchange and SafetyNet (Medicaid Managed Care, HARP, CHP, Essential Plan) lines of business: Requests for brand name Flolan or brand name Veletri, for NEW STARTS, **AND** EXISTING USERS at the time of recertification, will require documentation of serious side effects or drug failure with generic epoprostenol.
   Medicare lines of business: Requests for brand name Flolan or brand name Veletri, for NEW STARTS ONLY, will require documentation of serious side effects or drug failure with generic epoprostenol, **AND**
6. Must have had an adequate trial (defined as unacceptable or deteriorating clinical status despite the listed treatments) of either (a, b, or c)
   a. Two oral therapies from two different classes (i, ii, iii, or iv) alone or in combination:
      i. PDE5 inhibitor: sildenafil or tadalafil
      ii. ERA: ambrisentan, bosentan, or macitentan
      iii. Soluble guanylate cyclase stimulator (sGCS): Adempas (riociguat)
      iv. Oral or inhaled prostacyclin pathway agent (PPA): Uptravi, Tyvaso or Orenitram; **OR**
   b. One parenteral (IV or SC) prostacyclin (Flolan, Veletri, epoprostenol, Remodulin, treprostinil) **OR**
   c. One activin signaling inhibitor: Winrevair (sotatercept-csrk)
7. Patients classified as one of the following (a, b, c, or d) may bypass criterion 6:
   a. Patients with World Health Organization Functional Class (WHO-FC) III symptoms and evidence of rapidly progressing disease or other markers of poor clinical prognosis
   b. Patients with World Health Organization Functional Class (WHO-FC) IV symptoms
   c. Patients classified as high-risk based on one of the following risk stratification tools: ECS/ERS 3-risk strata, ECS/ERS 4 risk-strata, COMPERA 2.0, REVEAL 2.0, or REVEAL 2.0 Lite (see Appendix D)
   d. Patients classified as intermediate-risk patients based on the above risk stratification tools, with severe hemodynamic impairment (RAP ≥20 mmHg, CI <2.0 L/min/m^2, SVI <31 mL/m^2, and/or PVR ≥12 WU)

Letairis and generic ambrisentan – Pharmacy benefit

Ambrisentan is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1):

- To improve exercise ability and delay clinical worsening.
- In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
5. Requests for <u>brand name Letairis</u> will require documentation of serious side effects or drug failure with generic ambrisentan.

Dosing guidelines:

a. The maximum dose of Letairis / generic ambrisentan is 10mg once a day

Opsumit (macitentan), generic macitentan, and Opsynvi (macitentan and tadalafil) – Pharmacy benefit

Opsumit (macitentan): is an endothelin receptor antagonist (ERA) indicated for treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1) to reduce the risks of disease progression and hospitalization for PAH.

Opsynvi (macitentan/tadalafil): is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III.

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must be at least 18 years of age, **AND**
3. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
4. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
5. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
6. Step therapy applies – must have an adequate trial of at least one of the following oral <u>*preferred*</u> generic products with evidence of severe intolerance or drug failure / disease progression despite these treatments:
   a. PDE5 inhibitor: sildenafil or tadalafil
   b. ERA: ambrisentan or bosentan

Dosing guidelines:

a. Opsumit (macitentan) 10mg once a day. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.

b. Opsynvi (macitentan/tadalafil)
For patients who are treatment-naïve to any PAH specific therapy or transitioning from ERA monotherapy The recommended starting dose of Opsynvi is one 10 mg/20 mg tablet taken orally once daily with or without food for one week. If tolerated, up titrate Opsynvi to one 10 mg/40 mg tablet taken orally once daily with or without food as the maintenance dose. For patients transitioning from PDE5 inhibitor monotherapy or PDE5 inhibitor and ERA therapy in combination The recommended dose of Opsynvi is one 10 mg/40 mg tablet taken orally once daily.

Orenitram (treprostinil) – Pharmacy benefit

Orenitram (treprostinil): is a prostacyclin vasodilator indicated for Treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1) to delay disease progression and to improve exercise capacity.

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
5. Must have had an adequate trial (defined as unacceptable or deteriorating clinical status despite the listed treatments) of either (a, b, or c)
   a. Two oral therapies from two different classes (I, II, or III) alone or in combination:
      i. PDE5 inhibitor: sildenafil or tadalafil
      ii. ERA: ambrisentan, bosentan, or macitentan
      iii. Soluble guanylate cyclase stimulator (sGCS): Adempas; **OR**
   b. One PPA (Flolan, Veletri, epoprostenol, Tyvaso, Uptravi, Remodulin, treprostinil)
   c. One activin signaling inhibitor: Winrevair (sotatercept-csrk)

Dosing guidelines:
   a. The recommended starting dose of Orenitram is 0.25 mg twice daily (BID) with food, taken approximately 12 hours apart or 0.125 mg three times daily (TID) with food, taken approximately 8 hours apart. Increase the dose to the highest tolerated dose. Orenitram titration may be initiated with Orenitram Titration Kits or Orenitram tablets with appropriate titration schedule.
   b. There is no FDA approved maximum dose of oral Orenitram (treprostinil), but the maximum dose allowed within the clinical trials was 16mg twice a day.

Remodulin and generic treprostinil – Medical Benefit

Treprostinil is a prostacyclin vasodilator indicated for Treatment of pulmonary arterial hypertension (PAH) (World Health Organization group 1) in patients with New York Health Association Class II to IV symptoms to decrease exercise-associated symptoms; to diminish clinical deterioration when transitioning from epoprostenol

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**

- Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**

4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
5. Commercial, Exchange and SafetyNet (Medicaid Managed Care, HARP, CHP, Essential Plan) lines of business: Requests for brand name Remodulin, for NEW STARTS **AND** EXISTING USERS at the time of recertification, will require documentation of serious side effects or drug failure with generic treprostinil.
   Medicare lines of business: Requests for brand name Remodulin, for NEW STARTS ONLY, will require documentation of serious side effects or drug failure with generic treprostinil, **AND**
6. Must have had an adequate trial (defined as unacceptable or deteriorating clinical status despite the listed treatments) of either (a, b, or c)
   a. Two oral therapies from two different classes (i, ii, iii, or iv) alone or in combination:
      i. PDE5 inhibitor: sildenafil or tadalafil
      ii. ERA: ambrisentan, bosentan or macitentan
      iii. Soluble guanylate cyclase stimulator (sGCS): Adempas (riociguat)
      iv. Oral or inhaled prostacyclin pathway agent (PPA): Uptravi, Tyvaso or Orenitram; **OR**
   b. One parenteral (IV or SC) prostacyclin (Flolan, Veletri, epoprostenol, Remodulin, treprostinil) **OR**
   c. One activin signaling inhibitor: Winrevair (sotatercept-csrk)
7. Patients classified as one of the following (a, b, c, or d) may bypass criterion 6:
   a. Patients with World Health Organization Functional Class (WHO-FC) III symptoms and evidence of rapidly progressing disease or other markers of poor clinical prognosis
   b. Patients with World Health Organization Functional Class (WHO-FC) IV symptoms
   c. Patients classified as high-risk based on one of the following risk stratification tools: ECS/ERS 3-risk strata, ECS/ERS 4 risk-strata, COMPERA 2.0, REVEAL 2.0, or REVEAL 2.0 Lite
   d. Patients classified as intermediate-risk patients based on the above risk stratification tools, with severe hemodynamic impairment (RAP ≥20 mmHg, CI <2.0 L/min/m^2, SVI <31 mL/m^2, and/or PVR ≥12 WU)

Revatio / Liqrev / generic sildenafil – Pharmacy benefit

Sildenafil is a phosphodiesterase-5 enzyme inhibitor (PDE5) indicated for treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1):

- in adults to improve exercise ability and delay clinical worsening, and
- in pediatric patients 1 to 17 years old to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underly improvements in exercise

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required on all new and recertification requests, **AND**
5. Revatio and equivalent generic sildenafil will not be authorized for a diagnosis of erectile dysfunction as there are FDA approved medications for this diagnosis, **AND**
6. Requests for brand name Revatio will require documentation of serious side effects or drug failure with the equivalent generic sildenafil product indicated for a diagnosis of PAH.

7. Requests for brand name Liqrev suspension, Revatio suspension and sildenafil suspension will require:
   - Patient must be < 18 years of age, **OR**
   - For patients 18 years of age and older, there must be documentation of an inability to swallow whole tablets with documentation of inability to swallow provided

Dosing guidelines:

a. Adults: The recommended dosage of sildenafil is 20mg three times a day. Dose may be titrated to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability
b. Pediatric patients dosed by body weight as follows:
   - ≤20 kg the recommended dosage is 10 mg three times a day
   - 20 kg to 45 kg, the recommended dosage is 20 mg three times a day
   - 45 kg and greater, the recommended dosage is 20 mg three times a day.
   - A maximum dose in pediatric patients has not been identified. Based on the experience in adults, dose may be titrated to a maximum of 40 mg three times a day for pediatric patients >45 kg, if required, based on symptoms and tolerability

Tracleer / generic bosentan – Pharmacy Benefit

Bosentan is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1)
   - in adults to improve exercise ability and to decrease clinical worsening. **AND**
   - in pediatric patients ≥3 years of age with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR) which is expected to result in an improvement in exercise ability

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must be at least 3 years of age, **AND**
3. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
4. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
5. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required on all new and recertification requests, **AND**
6. Requests for brand name Tracleer will require documentation of severe intolerance or therapeutic failure with generic bosentan., **AND**
7. Member's current weight with date of measurement and requested dose regimen must be submitted with all new and recertification requests, **AND**
8. Quantity limit of generic bosentan/Tracleer 32mg is 30 tablets / 30 days. Quantity limit for generic bosentan/Tracleer 62.5mg and 125mg is 60 tablets / 30 days.
   a. Upon each drug review and dose escalation request, the allowed quantity will be reviewed in accordance with the FDA-approved weight-based dosing (see Table 1 below) and, as such, will be limited to the minimum number of oral tablets or tablets for oral suspension (dispersible tablets) of each strength to obtain the appropriate daily dose.

Dosing guidelines:

a. Maximum dose of Tracleer / bosentan is 125mg twice a day. Doses above 125 mg twice daily do not appear to confer additional benefit sufficient to offset the increased risk of hepatotoxicity.

Table 1 – FDA-approved weight-based dosing

Member age	Member weight (kg)	FDA approved dose regimen	Dosage form	Quantity per 30-day supply permitted upon review
3-12 years	4 to 8 kg	16 mg orally twice daily	Bosentan 32mg tablet	30
3-12 years	Greater than 8kg up to 16kg	32mg orally twice daily	Bosentan 32mg tablet	60
3-12 years	Greater than 16kg up to 24kg	48mg orally twice daily	Bosentan 32mg tablet	90
3-12 years	Greater than 24kg up to 40kg	64mg orally twice daily	Bosentan 32mg tablet	120
Older than 12 years	Less than 40kg	62.5mg orally twice daily	Bosentan 62.5mg tablet	60
Older than 12 years	Greater than 40kg	Initial 62.5mg twice daily for 4 weeks	Bosentan 62.5mg tablet	60
"	"	Then increase to maintenance dose of 125mg orally twice daily	Bosentan 125mg tablet	60

Tyvaso (treprostinil) inhalation, Tyvaso DPI, Yutrepia (treprostinil) – Pharmacy Benefit

Tyvaso (treprostinil) inhalation, Tyvaso DPI, and Yutrepia are a prostacyclin indicated for the treatment of:

- Pulmonary arterial hypertension (World Health Organization [WHO] group 1) in patients with NYHA Class III symptoms to improve exercise ability
- Pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability.

Drug Criteria for Pulmonary Arterial Hypertension (PAH):

Prostacyclins are generally not recommended as first- or second-line PAH treatments according to the 6th World Symposium on Pulmonary Hypertension and updated CHEST (American College of Chest Physicians) guidelines except in certain clinical scenarios noted below.

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
5. Must have had an adequate trial (defined as unacceptable or deteriorating clinical status despite the listed treatments) of either (a, b, or c)
   a. Two oral therapies from two different classes (I, II, or III) alone or in combination:
      i. PDE5 inhibitor: sildenafil or tadalafil
      ii. ERA: ambrisentan, bosentan, or macitentan
      iii. Soluble guanylate cyclase stimulator (sGCS): Adempas; **OR**
   b. One PPA (Flolan, Veletri, epoprostenol, Tyvaso, Uptravi, Remodulin, treprostinil)
   c. One activin signaling inhibitor: Winrevair (sotatercept-csrk)

Dosing guidelines:

a. Tyvaso inhalation solution: Studies evaluating effectiveness used a target dose of 54 mcg (9 inhalations) four times per day.
b. Tyvaso DPI: Target dose of 48 to 64 mcg inhaled per session, four times per day

Please note: Tyvaso DPI Titration Kits are intended for new patients titrating to their target maintenance dose. Once patients are on a stable target maintenance dose, they should be transitioned to a maintenance kit product.

c. Yutrepia: In Treprostinil-naïve patients, therapy should begin with 26.5 mcg 3 to 5 times per day, in 2 breaths based on patient response. Dosing in patients transitioning from treprostinil inhalation solution (Tyvaso), can begin Yutrepia therapy 3 to 5 times per day, in 2 breaths, using the doses specified in FDA prescribing information. In treprostinil-naïve patients and those transitioning from treprostinil inhalation solution, dose increases of 26.5 mcg per dose each week may be implemented, as tolerated. The target maintenance dosage is 79.5 mcg to 106 mcg, 4 times daily. Doses above 848 mcg per day have not been studied in patients with PAH.

Drug Criteria for Pulmonary hypertension associated with interstitial lung disease [PH-ILD, World Health Organization (WHO) group III]

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of pulmonary hypertension and chronic lung disorders, **AND**
2. Must be at least 18 years of age, **AND**
3. Must have a diagnosis of WHO group 3 pulmonary hypertension associated with interstitial lung disease [such as idiopathic pulmonary fibrosis (IPF), idiopathic interstitial pneumonia, WHO group 3 connective tissue disease, chronic hypersensitivity pneumonitis, combined pulmonary fibrosis and emphysema (CPFE)], **AND**
4. Right heart catheterization confirms pulmonary hypertension in the setting of chronic lung disease (documentation required):
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
5. High-resolution CT scan finding characteristic airway and/or parenchymal abnormalities associated with interstitial lung disease, **AND**
6. Must have clinical symptoms associated with PH-ILD such as shortness of breath with exertion that is not fully explained by the severity of lung disease, decreased exercise capacity, labored breathing, fatigue, lethargy **AND**
7. Baseline 6-minute walk test to assess disease severity and clinical response to treatment, **AND**
8. Baseline NT-proBNP [N-terminal pro–B-type natriuretic peptide] level, **AND**
9. Progress notes are required to be submitted with requests for initial coverage and existing users,
10. Initial approval will be for 6 months
11. Recertification will require documentation of stabilization or improvement in 6MWT from baseline, decrease in NT-proBNP levels as well as stabilization or reduction in disease severity such as improvements in FVC, reduction in exacerbations of the underling lung disease and clinical worsening.

Dosing guidelines:

a. Tyvaso Inhalation Solution: Studies establishing effectiveness used a target dose of 72 mcg (12 inhalations) four times per day

b. Tyvaso DPI: Target dose of 48 to 64 mcg inhaled per session, four times per day.
Note: Tyvaso DPI Titration Kits are intended for new patients titrating to their target maintenance dose. Once patients are on a stable target maintenance dose, they should be transitioned to a maintenance kit product.

c. Yutrepia: In Treprostinil-naïve patients, therapy should begin with 26.5 mcg 3 to 5 times per day, in 2 breaths based on patient response. Dosing in patients transitioning from treprostinil inhalation solution (Tyvaso), can begin Yutrepia therapy 3 to 5 times per day, in 2 breaths, using the doses specified in FDA prescribing information. In treprostinil-naïve patients and those

transitioning from treprostinil inhalation solution, dose increases of 26.5 mcg per dose each week may be implemented, as tolerated. The target maintenance dosage is 79.5 mcg to 106 mcg, 4 times daily. Doses above 848 mcg per day have not been studied in patients with PAH.

Uptravi (selexipag) – Rx & Medical

Uptravi (selexipag): is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults and pediatric patients ≥ 2 years to delay disease progression and reduce the risk of hospitalization for PAH

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must be at least 2 years of age, **AND**
3. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), **AND**
4. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
5. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP and PVR) are required for all requests, **AND**
6. Must have had an adequate trial (defined as unacceptable or deteriorating clinical status despite the listed treatments) of either (a, b, or c)
   a. Two oral therapies from two different classes (i, ii, or iii) alone or in combination:
      I. PDE5 inhibitor: sildenafil or tadalafil
      II. ERA: ambrisentan, bosentan, or macitentan
      III. Soluble guanylate cyclase stimulator (sGCS): Adempas; **OR**
   b. One PPA (Flolan, Veletri, epoprostenol, Tyvaso, Uptravi, Remodulin, treprostinil)
   c. One activin signaling inhibitor: Winrevair (sotatercept-csrk)
7. UPTRAVI TABLETS - The initial approval for Uptravi will be for 6 months to allow for dose titration. If after the initial 6-month approval the dose is still being titrated then an additional 6 months will be authorized, **AND**
8. Subsequent requests for UPTRAVI TABLETS will be evaluated yearly for dose efficiency (i.e., a dose of 800mcg will require the use of 800mcg tablets in lieu of combining lower strength tablets to achieve the same dose.).
9. UPTRAVI for INJECTION – Indicated for patients who are temporarily unable to take oral therapy.
   a. Uptravi for injection will be covered under the member's *medical benefit.*
   b. Uptravi for injection is administered twice daily by IV infusion at a dose that corresponds to the patient's current dose of Uptravi tablets (please refer to the FDA approved package labelling for the equivalent IV dosage).
   c. Approval will be for 1 month.
   d. Recertification requires documentation of continued medical necessity of Uptravi for injection and inability to take oral therapy.

Dosing guidelines:

a. Adults (maximum dose allowed):
   I. Uptravi (selexipag) tablets is 1,600 mcg twice daily
   II. Uptravi (selexipag) IV infusion is 1800 mcg (equivalent to 1600 mcg oral dose) twice daily.
b. Pediatric patients dose by body weight (maximum dose allowed):
   I. 9 kg to < 25 kg: 800 mcg orally twice daily
   II. 25 kg to < 40 kg: 1,200 mcg orally twice daily
   III. ≥ 40 kg: 1,600 mcg orally twice daily

Winrevair (sotatercept-csrk) - Rx & Medical

1. Must be prescribed by a cardiologist or pulmonologist experienced in the treatment of Pulmonary Arterial Hypertension (PAH), **AND**
2. Must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension, **AND**
3. The diagnosis of PAH must be confirmed by Right Heart Catheterization (RHC) documenting:
   - Mean pulmonary artery pressure (mPAP) of > 20 mmHg at rest, **AND**
   - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg at rest, **AND**
   - Pulmonary Vascular Resistance (PVR) > 2 wood units (WU), **AND**
4. Progress notes including relevant diagnostic test results (including Right Heart Catheterization report clearly documenting mPAP, PCWP, and PVR) and current World Health Organization Functional Class are required for all requests, **AND**
5. Must be World Health Organization functional class II, III, or IV pulmonary arterial hypertension, **AND**
6. Must be established and stable on baseline therapy of at least two, standard of care, advanced therapies FDA approved to treat pulmonary arterial hypertension, from two different classes for at least 3 months such as:
   - PDE5 inhibitor: sildenafil or tadalafil
   - ERA: ambrisentan, bosentan, macitentan
   - sGCS: Adempas (riociguat);
   - PPA: epoprostenol, treprostinil (oral, inhaled, or parenteral), Uptravi; **AND**
7. Must have clinical symptoms of PAH despite current combination therapy **AND**
8. Documentation of baseline 6-minute walk distance **OR** baseline NT-proBNP **OR** baseline WHO functional class (measured prior to the start of Winrevair but on at least dual therapy as described in 6 above), **AND**
9. Prescriber must submit the member's current weight with starting dosage in milligrams, target dosage in milligrams and the dose frequency of administration.
10. Winrevair is limited to a quantity of one kit every 21 days.

Initial approval timeframe – 6 months
1st Recertification criteria – 12 months
1. Must have documentation of ONE of the following:
   a. Repeat 6-minute walk test showing an improvement or no worsening compared to baseline, **OR**
   b. Lab report documenting current NT-proBNP level with a decrease of ≥ 30% (or maintenance/achievement of NT-proBNP level < 300 pg/mL), **OR**
   c. Stabilization or improvement in WHO functional class **AND**
2. Documented improvement and/or maintenance in clinical symptoms of PAH **AND**
3. Current weight with target dosage in milligrams and the dose frequency of administration.

Second recertification and ongoing: 2 years
1. Improved or maintained 6-minute walk test, NT-proBNP, and/or functional class and clinical symptoms, **AND**
2. Current weight with target dosage in milligrams and the dose frequency of administration.

Dose information:
   a. The recommended starting dose is Winrevair 0.3mg/kg for one dose, then 0.7mg/kg every 21 days thereafter. Dose adjustments may be needed based on laboratory monitoring of platelet and hemoglobin and will be determined by the prescriber. Dose is based on actual body weight.
   b. Package labelling:

Starting dose:

Injection volume for starting dose is calculated based on patient weight as follows:

$$Injection\ Volume\ (mL) = \frac{Weight\ (kg)\ x\ 0.3\ mg/kg}{50\ mg/mL}$$

Injection volume should be rounded to the nearest 0.1 mL.

For example: (70 kg x 0.3 mg/kg) ÷ 50 mg/mL = 0.42 mL, rounds to 0.4 mL

See Table 1 for selecting the appropriate kit based on calculated injection volume for starting dose.

Table 1: Kit Type Based on Injection Volume for Dose of 0.3 mg/kg

Injection Volume (mL)	Kit Type
0.2 to 0.9	45 mg kit (containing 1 x 45 mg vial)
1 to 1.1	60 mg kit (containing 1 x 60 mg vial)

c. Target Dose

Injection volume for target dose is calculated based on patient weight as follows:

$$Injection\ Volume\ (mL) = \frac{Weight\ (kg)\ x\ 0.7\ mg/kg}{50\ mg/mL}$$

Injection volume should be rounded to the nearest 0.1 mL.

For example: (70 kg x 0.7 mg/kg) ÷ 50 mg/mL = 0.98 mL, rounds to 1 mL

Table 2: Kit Type Based on Injection Volume for Dose of 0.7 mg/kg

Injection Volume (mL)	Kit Type
0.4 to 0.9	45 mg kit (containing 1 x 45 mg vial)
1 to 1.2	60 mg kit (containing 1 x 60 mg vial)
1.3 to 1.8	90 mg kit (containing 2 x 45 mg vials)
1.9 to 2.4	120 mg kit (containing 2 x 60 mg vials)

APPROVAL TIME PERIODS:

Line of Business	Pharmacy benefit Initial approval	Pharmacy benefit Continued approval	Medical Benefit Initial approval	Medical Benefit Continued Approval
Commercial, Exchange and SafetyNet (Medicaid, HARP, CHP, Essential Plan)	2 years *Does not apply to Medicaid and HARP	2 years *Does not apply to Medicaid and HARP	2 years	2 years
Medicare	Defined in Medicare Drug Policy	Defined in Medicare Drug Policy	2 years	2 years

POLICY GUIDELINES:

1. Unless otherwise stated above within the criteria, approval time-periods are listed in the table above.
   - Continued approval at time of recertification will require documentation that the drug is providing ongoing benefit to the patient in terms of improvement or stability in disease state or condition.
2. Clinical documentation must be submitted for each request (initial and recertification) unless otherwise specified (e.g., provider attestation required). Supporting documentation includes, but is not limited to, progress notes documenting previous treatments/treatment history, diagnostic testing, laboratory test results, genetic testing/biomarker results, imaging and other objective or subjective measures of benefit which support continued use of the requested product is medically necessary. Also, ongoing use of the requested product must continue to reflect the current policy's preferred

formulary. Recertification reviews may result in the requirement to try more cost-effective treatment alternatives as they become available (i.e., generics, biosimilars, or other guideline supported treatment options). Requested dosing must continue to be consistent with FDA-approved or off-label/guideline-supported dosing recommendations.

3. Utilization Management is contract dependent and coverage criteria may be dependent on the contract renewal date. Additionally, coverage of drugs listed in this policy are contract dependent. Refer to specific contract/benefit language for exclusions.
4. For contracts where Insurance Law § 4903(c-1), and Public Health Law § 4903(3-a) are applicable, if trial of *preferred* drug(s) is the only criterion that is not met for a given condition, and one of the following circumstances can be substantiated by the requesting provider, with medical rationale **AND** supporting documentation, then trial of the *preferred* drug(s) will not be required.
   - The required prescription drug(s) is/are contraindicated or will likely cause an adverse reaction or physical or mental harm to the member.
   - The required prescription drug is expected to be ineffective based on the known clinical history and conditions and concurrent drug regimen.
   - The required prescription drug(s) was (were) previously tried while under the current or a previous health plan, or another prescription drug or drugs in the same pharmacologic class or with the same mechanism of action was (were) previously tried and such prescription drug(s) was (were) discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.
   - The required prescription drug(s) is (are) not in the patient's best interest because it will likely cause a significant barrier to adherence to or compliance with the plan of care, will likely worsen a comorbid condition, or will likely decrease the ability to achieve or maintain reasonable functional ability in performing daily activities.
   - The individual is stable on the requested prescription drug. The medical profile of the individual (age, disease state, comorbidities), along with the rational for deeming stability as it relates to standard medical practice and evidence-based practice protocols for the disease state will be taken into consideration.
5. The above criteria are not applicable to requests for brand name medications that have an AB rated generic. We can require a trial of an AB-rated generic equivalent prior to providing coverage for the equivalent brand name prescription drug
6. This policy is applicable to drugs that are included on a specific drug formulary (Rx benefit only). If a drug referenced in this policy is non-formulary, please reference the Coverage Exception Evaluation Policy for All Lines of Business Formularies policy for review guidelines.
7. Supportive documentation of previous drug use must be submitted for any criteria that require a trial of a preferred agent if the preferred drug is not found in claims history.
8. Dose and frequency should be in accordance with the FDA label or recognized compendia (for off label uses). When services are performed in excess of established parameters, they may be subject to review for medical necessity.
9. This policy does not apply to Medicare Part D and D-SNP pharmacy benefits. The drugs in this policy may apply to all other lines of business including Medicare Advantage.
10. For members with Medicare Advantage, medications with a National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) will be covered pursuant to the criteria outlined by the NCD and/or LCD. NCDs/LCDs for applicable medications can be found on the CMS website at https://www.cms.gov/medicare-coverage-database/search.aspx. Indications that have not been addressed by the applicable medication's LCD/NCD will be covered in accordance with criteria determined by the Health Plan (which may include review per the Health Plan's Off-Label Use of FDA Approved Drugs policy). Step therapy requirements may be imposed in addition to LCD/NCD requirements.

11. All requests will be reviewed to ensure they are being used for an appropriate indication and may be subject to an off-label review in accordance with our Off-Label Use of FDA Approved Drugs Policy (Pharmacy-32).
12. All utilization management requirements outlined in this policy are compliant with applicable New York State insurance laws and regulations. Policies will be reviewed and updated as necessary to ensure ongoing compliance with all state and federally mandated coverage requirements.

CODES:

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

Codes may not be covered under all circumstances. Please read the policy and guidelines statements carefully
Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
Code Key: Experimental/Investigational = (E/I), Not medically necessary / appropriate = (NMN).
Copyright © 2006 American Medical Association, Chicago, IL

HCPCS

J1325	Flolan, Veletri, generic epoprostenol
J3285	Remodulin, generic treprostinil
J7686	Tyvaso (treprostinil, inhalation solution)

Appendix A:

Pulmonary Hypertension (PH) WHO Classification	
Group 1	PAH (pulmonary arterial hypertension)
Group 2	PH due to left heart disease
Group 3	PH due to lung disease and/or hypoxemia
Group 4	PH due to pulmonary artery obstructions; CTEPH (chronic thromboembolic pulmonary hypertension)
Group 5	PH due to unclear multifactorial mechanisms

Clinical classification of pulmonary hypertension

- **GROUP 1** Pulmonary arterial hypertension (PAH)
  - 1.1 Idiopathic
    - 1.1.1 Non-responders at vasoreactivity testing
  - 1.2 Heritable
  - 1.3 Associated with drugs and toxins
  - 1.4 Associated with:
    - 1.4.1 Connective tissue disease
    - 1.4.2 HIV infection
    - 1.4.3 Portal hypertension
    - 1.4.4 Congenital heart disease
    - 1.4.5 Schistosomiasis
  - 1.5 PAH with features of venous/capillary (PVOD/PCH) involvement
  - 1.6 Persistent PH of the newborn
- **GROUP 2** PH associated with left heart disease
  - 2.1 Heart failure:
    - 2.1.1 with preserved ejection fraction
    - 2.1.2 with reduced or mildly reduced ejection fraction
    - 2.1.3 cardiomyopathies with specific etiologies
  - 2.2 Valvular heart disease

        - 2.2.1 aortic valve disease
        - 2.2.2 mitral valve disease
        - 2.2.3 mixed valvular disease
    - 2.3 Congenital/acquired cardiovascular conditions leading to post-capillary PH
- **GROUP 3** PH associated with lung diseases and/or hypoxia
    - 3.1 Obstructive lung disease or emphysema
    - 3.2 Restrictive lung disease
    - 3.3 Lung disease with mixed restrictive/obstructive pattern
    - 3.4 Hypoventilation syndromes
    - 3.5 Hypoxia without lung disease (e.g., high altitude)
        - 3.5.1 hypoventilation syndromes
        - 3.5.2 pneumonectomy
    - 3.6 Developmental lung disorders
    - 3.7 Developmental lung diseases
- **GROUP 4** PH associated with pulmonary artery obstructions
    - 4.1 Chronic thrombo-embolic PH
    - 4.2 Other pulmonary artery obstructions
- **GROUP 5** PH with unclear and/or multifactorial mechanisms
    - 5.1 Hematological disorders
    - 5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis and neurofibromatosis type 1
    - 5.3 Metabolic disorders
    - 5.4 Chronic renal failure with or without hemodialysis
    - 5.5 Pulmonary tumor thrombotic microangiopathy
    - 5.6 Fibrosing mediastinitis
    - 5.7 Complex congenital heart disease

PAH: pulmonary arterial hypertension
PVOD: pulmonary veno-occlusive disease
PCH: pulmonary capillary hemangiomatosis
PH: pulmonary hypertension
LVEF: left ventricular ejection fraction

Hemodynamic definitions of pre- and post-capillary pulmonary hypertension

Definitions	Characteristics	Typical Clinical groups (see list above)
Pulmonary hypertension (PH)	mPAP > 20 mm Hg	All
Pre-capillary PH	mPAP >20 mmHg PAWP ≤15 mmHg PVR > 2 WU	Pulmonary arterial hypertension PH attributable to lung disease CTEPH
Combined pre- and post-capillary PH (CpcPH)	mPAP > 20 mm Hg PVR > 2 WU PAWP > 15 mm Hg	Left heart disease Left heart + lung disease overlap
Isolated post-capillary PH (IpcPH)	mPAP >20 mmHg PAWP >15mmHg PVR ≤ 2 WU	Left heart disease
Exercise PH	mPAP/CO slope between rest and exercise > 3 mm Hg/L per min	Exertional dyspnea with preserved LV ejection fraction with normal resting PAWP

Appendix B:

New York Heart Association Functional Classification	
Class 1	Ordinary physical activity does not cause symptoms
Class 2	Comfortable at rest, ordinary physical activity causes symptoms

Class 3	Comfortable at rest, less than ordinary activity (ADLs) causes symptoms
Class 4	Symptoms at rest

Appendix C:

World Health Organization Functional Classification of Patients With PH	
Class 1	Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
Class 2	Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class 3	Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope
Class 4	Patients with PH with inability to carry out any physical activity without symptoms. These patients' manifest signs of right-sided heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity

Appendix D:
Risk Stratification Tools (Figures 1 and 2):
Risk stratification and treatment goals in pulmonary arterial hypertension | European Respiratory Society

UPDATES:

Date:	**Revision**
09/14/2026	Revised (P&T Committee reviewed and approved on 08/13/2026)
08/13/2026	Reviewed / P&T Committee Approval
06/08/2026	Revised
05/14/2026	Reviewed / P&T Committee Approval
03/05/2026	Revised
02/04/2026	Revised
01/01/2026	Revised
11/04/2025	Revised
09/22/2025	Revised
08/08/2025	Revised
05/08/2025	Reviewed / P&T Committee Approval
03/06/2025	Revised
12/19/2024	Revised
11/01/2024	Revised
07/09/2024	Revised
06/24/2024	Revised
05/21/2024	Revised
05/10/2024	P&T Committee Approval
04/23/2024	Revised
12/06/2023	Revised
06/08/2023	Revised
05/11/2023	P&T Committee Approval
04/27/2023	Revised

04/01/2023	Revised
10/05/2022	Revised
06/24/2022	Revised
05/05/2022	P&T Committee Approval
04/26/2022	Revised
03/21/2022	Revised
09/01/2021	Revised
07/27/2021	Revised
05/06/2021	Reviewed & P&T Committee Approval
04/19/2021	Revised
09/16/2020	Reviewed & P&T Committee Approval
08/25/2020	Revised
07/08/2020	Revised
4/14/2020	Revised
2/19/2020	Revised
11/19/2019	Reviewed
3/26/2019	Revised
10/1/2018	Revised
4/19/18	Revised
9/26/17	Revised
4/20/17	Reviewed
1/2016,	Revised
8/2014	Revised
6/2014	Revised
12/2013	Revised
8/2013	Revised
7/2013	Revised
2/2011	Revised
6/2005	Created

REFERENCES:

In addition to the full FDA approved prescribing information for each individual drug, the following references have been utilized in creating this policy and specific drug criteria:

Pulmonary Arterial Hypertension

1. Badesch D, et al. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines. CHEST 2004; 126:35S-57S.
2. Sitbon O, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384-89.
3. Sitbon O, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265-70.
4. Opitz CF, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24:356-65.
5. Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Eng J Med 1996; 334:296-302.

6. Rich S, et al. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1184-7.
7. Shapiro SM, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343-9.
8. McLaughlin VV, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 40:780-8.
9. Simonneau G, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-4.
10. Hoeper MM, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 2000; 342:1866-70.
11. Channick RN, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358:1119-23.
12. Michelakis E, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-403.
13. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006 Dec;28(6):1195-203.
14. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8):1672-81.
15. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007 Sep;132(3):757-63.
16. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48(7):1433-7.
17. McLaughlin VV et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J of American College of Cardiology. 53(17)2009.
18. Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2009:30:2493-2537.
19. Taichman DB et al. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline and Expert Panel Report. *Chest.* 2014;146(2):449-475.
20. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44.
21. Galie N, Humbert M, Vachiery J-L, et. al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. (2016) 37, 67–119
22. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension. *N Engl J Med*. 1992;327(2):76-81.
23. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*. 2005;111(23):3105-3111.
24. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2010;31(15):1898-1907
25. Sauler M, Fares WH, Trow TK. Standard nonspecific therapies in the management of pulmonary arterial hypertension. Clin Chest Med. 2013 Dec;34(4):799-810
26. Matsubara H, Ogawa A. Treatment of idiopathic/hereditary pulmonary arterial hypertension. J Cardiol. 2014 Oct;64(4):243-9

27. Updated treatment algorithm of pulmonary arterial hypertension. Journal of the American College of Cardiology, ISSN: 1558-3597, Vol: 62, Issue: 25 Suppl, Page: D60-72; 2013
28. Simonneau G, Montani D, Celermaier D, et. al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal Jan 2019, 53 (1):1-13.
29. Klinger J, Elliott C, Levine D, et. al. Therapy for Pulmonary Arterial Hypertension in Adults. Update of the CHEST Guideline and Expert Panel Report. Chest 2019; 155(3): 565-586
30. Schnur M. Systemic Vascular Resistance and Pulmonary Vascular Resistance: What's the Difference? https://www.nursingcenter.com/ncblog/may-2017/systemic-vascular-resistance-and-pulmonary-vascula
31. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal (2022) 43, 3618-3731
32. Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, McLaughlin VV, Sitbon O. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J.
33. Sahay S, Tonelli AR, Farber HW. Pulmonary arterial hypertension: current practice and future directions. Pulm Circ. 2024;14(2):e12345. doi:10.1177/20458940241234567.
34. Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401323. doi:10.1183/13993003.01323-2024

Pediatric Pulmonary Arterial Hypertension

35. Frank B, Ivy D. Pediatric Pulmonary Arterial Hypertension. Pediatri Clin N Am 67 (2020) 903-921.
36. Hansmann G, Koestenberger M. et. al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. The Journal of Heart and Lung Transplantation. September 2019
37. Abman S, Hansmann G, et. al. Pediatric Pulmonary Hypertension. Circulation. 2015; 132:2037-2099.
38. pitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii23-ii29

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

39. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915
40. Wilkens H, Kostantinides S, Lang I, et. al. Chronic Thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne consensus Conference 2019. International Journal of Cardiology 272 (2018) 69–78

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

41. Waxman A, Restrop-Jaramillo, Thenappan T, et.al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021;384:325-34.
42. King C. Shlobin O. The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease. Dilemmas in Diagnosis and the Conundrum of Treatment. Chest 2020;158(4):1651-1664.